Abstract
Background and objective Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation having multiple advantages over other support modalities but data about effectiveness are limited.
Methods In this multicenter randomized trial of helmet non-invasive ventilation for COVID-19 patients (Helmet-COVID), 320 adult ICU patients with suspected or confirmed COVID-19 and acute hypoxemic respiratory failure (with a ratio of arterial oxygen partial pressure to fraction (percent) of inspired oxygen (PaO2/FiO2) <200 despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate >10 L/min or above) will be randomized to helmet-noninvasive ventilation with usual care or usual care alone. The primary outcome is death from any cause within 28 days after randomization. The trial has 80% power to detect a 15% absolute risk reduction from 40% to 25%.
Conclusion Consistent with international guidelines, we developed a detailed plan to guide the analysis of the Helmet-COVID trial. This plan specifies the statistical methods for the evaluation of primary and secondary outcomes to facilitate unbiased analyses of clinical data.
Trial registration Clinicaltrials.gov: NCT04477668 (registered on July 20, 2020)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Clinicaltrials.gov: NCT04477668
Funding Statement
The study is funded by King Abdullah International Medical Research Center (RC 20/306/R). The study sponsor does not have any role in the study design, collection, management, analysis, and interpretation of data as well as the writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the Institutional Review Boards of King Abdulaziz Medical City- Riyadh; Aseer Central Hospital-Abha; King Fahad Hospital-Madinah; King Abdulaziz University Hospital-Jeddah; King Faisal Specialist Hospital and Research Center- Riyadh; King Fahad Hospital of the University- Dammam; King Khalid University Hospital-Riyadh; King Salman Specialist Hospital-Hail; King Saud Medical City-Riyadh
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
yaseenarabi{at}yahoo.com
tlayjehh{at}ngha.med.sa
DakheelS{at}NGHA.MED.SA
aldorzih{at}yahoo.com
abdukahil.sheryl{at}gmail.com
joseje{at}ngha.med.sa
HarbiMK{at}NGHA.MED.SA
HajiH{at}NGHA.MED.SA
MutairyMM{at}NGHA.MED.SA
ZumaiO{at}NGHA.MED.SA
Eman77al-qasim{at}hotmail.com
wedyan.mohammed{at}outlook.com
mcmasterer{at}hotmail.com
msshahrani{at}iau.edu.sa
talbrahim{at}iau.edu.sa
afmady{at}hotmail.com
albshabshe{at}yahoo.com
zohairalaseri{at}yahoo.com
zalduhailib65{at}kfshrc.edu.sa
a7yman{at}hotmail.com
arakan{at}KSU.EDU.SA
halgethamy2020{at}gmail.com
ALFARISOM{at}NGHA.MED.SA
dr.alnafal1{at}gmail.com
abdulrahman.alfares{at}gmail.com
Data Availability
Once all planned analyses have been completed and published or presented, data will be shared upon reasonable request from the Chief Investigator.
List of abbreviations
- CI
- Confidence Interval
- HR
- Hazard Ratio
- ICU
- Intensive Care Unit
- IQR
- Interquartile Range
- LOS
- Length of stay
- RT-PCR
- Reverse Transcription–Polymerase Chain Reaction
- RCT
- Randomized Controlled Trial
- RR
- Relative Risk
- RRR
- Relative Risk Reduction
- SAP
- Statistical Analysis Plan